The new MRI contrast agent gadopiclenol, sold under the trade names Elucirem and Vueway by Bracco and Guerbet, uses 50% less gadolinium than current MRI agents.
The ACR Committee on Drugs and Contrast Media stated that exposure to the gadolinium-based contrast agent represents a “sufficiently low or possibly nonexistent” risk to patients.
These findings warrant serious consideration by physicians caring for pregnant women in the future, as the link between poor mental health and placental development remains “underappreciated.”
FFR-CT has grown in popularity due its ability to provide noninvasive evaluations of patients being considered for revascularization procedures. According to a new study in JACC: Cardiovascular Imaging, however, stress imaging strategies may still provide more value in certain scenarios.